Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Netarsudil (Rhopressa) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The fixed-dose combination (FDC) therapy of netarsudil and latanoprost showed superior efficacy in reducing intraocular pressure compared to both netarsudil and latanoprost monotherapies.
• Two studies that evaluated the safety and effectiveness of Rhopressa (netarsudil) alone, as well as its FDC with latanoprost, have been examined.
• In terms of efficacy, the FDC had significantly lower mean diurnal IOP than either drug used individually. Compared to netarsudil alone, it achieved a mean difference (MD) of -2.36; when compared to latanoprost alone, the MD was -1.64.
• Regarding safety considerations, while total adverse events were similar between netarsudil and the FDC therapy, they were higher for these treatments compared to using latanoprost on its own.
• Both the monotherapy form of Rhopressa and its combined use with latanoprost have been associated with an increased risk of conjunctival hyperemia relative to treatment involving only latanoprost; however, symptoms are mostly mild, leading to low discontinuation rates due to this side effect, suggesting manageability among the majority of patients despite higher risks involved.
• A significant number of diverse population samples from studies indicate that Rhopressa could benefit those requiring more aggressive IOP reduction or who might not have responded optimally to monotherapies, thus making it a promising option for enhancing IOP reduction among glaucoma patients. However, careful selection is advised given the potential increase in adverse effects, especially among individuals susceptible to such side effects.